Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Keratosis, Actinic 18Keratosis 3Condylomata Acuminata 3Carcinoma, Basal Cell 3Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Glioblastoma 2Warts 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Sialorrhea 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 2Interferon beta-1b 2Gemcitabine 2pembrolizumab 1enfortumab vedotin 1cemiplimab 1apaziquone 1Standard of Care 1Oncolytic Virotherapy 1Interferons 1Imiquimod 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma in Situ × Imiquimod × Clear all
NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Telormedix SA

Phase 2 Completed
12 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡